瑞典前列腺癌诊断中人工智能辅助病理的有效性与成本效果:一项微观模拟研究
该微观模拟研究评估在瑞典50至74岁男性中每四年一次PSA筛查下,AI辅助病理诊断前列腺癌的有效性与成本效果。与仅病理医生评估相比,AI辅助工作流程使病理医生评估的活检芯比例减少80%,在每例10欧元成本下费用更低且QALYs降低<0.001%。模型显示AI辅助病理可显著减少病理医生工作量、不影响患者生活质量并在瑞典节约成本。
要点
- AI辅助病理使病理医生评估的活检芯比例减少80%。
- 每例10欧元成本下,AI辅助工作流程费用更低且QALYs降低<0.001%。
- 模型显示AI辅助病理可显著减少病理医生工作量并在瑞典节约成本。
核心结论
- 根据该模型,与仅由人类病理医生评估相比,AI辅助病理将显著减少病理医生的工作量,不会影响患者生活质量,并在瑞典产生成本节约。
研究设计与样本
- 微观模拟研究,模拟瑞典50至74岁男性每四年一次PSA筛查,采用终身时间范围和医疗保健视角。
- PSA≥3 ng/ml的男性转诊接受标准活检,活检芯或先经AI评估、AI标记为阳性的活检芯再由病理医生评估,或仅由病理医生评估。
- AI性能特征使用内部STHLM3验证数据集估计。
主要发现
- 与仅病理医生相比,AI辅助工作流程使PSA检测数、标准活检数和前列腺癌死亡数增加≤0.03%。
- 与仅病理医生相比,AI辅助工作流程略微降低前列腺癌发病率和过度诊断。
- AI使病理医生评估的活检芯比例减少80%。
- 在每例10欧元成本下,与仅病理医生相比,AI辅助工作流程费用更低且QALYs降低<0.001%。
- 结果对AI成本敏感。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Image-based artificial intelligence (AI) methods have shown high accuracy in prostate cancer (PCa) detection. Their impact on patient outcomes and cost effectiveness in comparison to human pathologists remains unknown. Our aim was to evaluate the effectiveness and cost-effectiveness of AI-assisted pathology for PCa diagnosis in Sweden. METHODS: We modeled quadrennial prostate-specific antigen (PSA) screening for men between the ages of 50 and 74 yr over a lifetime horizon using a health care perspective. Men with PSA ≥3 ng/ml were referred for standard biopsy (SBx), for which cores were either examined via AI followed by a pathologist for AI-labeled positive cores, or a pathologist alone. The AI performance characteristics were estimated using an internal STHLM3 validation data set. Outcome measures included the number of tests, PCa incidence and mortality, overdiagnosis, quality-adjusted life years (QALYs), and the potential reduction in pathologist-evaluated biopsy cores if AI were used. Cost-effectiveness was assessed using the incremental cost-effectiveness ratio. KEY FINDINGS AND LIMITATIONS: In comparison to a pathologist alone, the AI-assisted workflow increased the number of PSA tests, SBx procedures, and PCa deaths by ≤0.03%, and slightly reduced PCa incidence and overdiagnosis. AI would reduce the proportion of biopsy cores evaluated by a pathologist by 80%. At a cost of €10 per case, the AI-assisted workflow would cost less and result in <0.001% lower QALYs in comparison to a pathologist alone. The results were sensitive to the AI cost. CONCLUSIONS AND CLINICAL IMPLICATIONS: According to our model, AI-assisted pathology would significantly decrease the workload of pathologists, would not affect patient quality of life, and would yield cost savings in Sweden when compared to a human pathologist alone. PATIENT SUMMARY: We compared outcomes for prostate cancer patients and relevant costs for two methods of assessing prostate biopsies in Sweden: (1) artificial intelligence (AI) technology and review of positive biopsies by a human pathologist; and (2) a human pathologist alone for all biopsies. We found that addition of AI would reduce the pathology workload and save money, and would not affect patient outcomes when compared to a human pathologist alone. The results suggest that adding AI to prostate pathology in Sweden would save costs.
引用
- Du X, Hao S, Olsson H, et al. Effectiveness and Cost-effectiveness of Artificial Intelligence-assisted Pathology for Prostate Cancer Diagnosis in Sweden: A Microsimulation Study. Eur Urol Oncol. 2024. PMID: 38789385. doi:10.1016/j.euo.2024.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。